| ERYTHROMYCIN ETHYLSUCCINATE
Apo-Erythro-ES , E.E.S., E.E.S.-200, E.E.S.-400, EryPed, Pediamycin
Classifications: macrolide antibiotic; Therapeutic: antibiotic
Pregnancy Category: B
200 mg chewable tablet, 400 mg tablets; 100 mg/2.5 mL, 200 mg/5 mL, 400 mg/5 mL suspension
Macrolide antibiotic that binds to the 50S ribosomal subunit of bacteria, thus inhibiting bacterial protein synthesis.
More active against gram-positive than gram-negative bacteria.
Hypersensitivity to erythromycins or any macrolide antibiotic; history of erythromycin-associated hepatitis; preexisting liver
disease; congenital QT prolongation; electrolyte imbalances.
Myasthenia gravis; history of GI disease; seizure disorders; pregnancy (category B), lactation.
Route & Dosage
Adult: PO 400 mg q6h up to 4 g/d according to severity of infection
Child: PO 3050 mg/kg/d in 4 divided doses (max: 100 mg/kg/d) for severe infections
- Chewable tablets should be chewed and not swallowed whole.
- Suspensions are stable for 14 d at room temperature unless otherwise stated by manufacturer. Note expiration date.
- Store tablets in tight containers unless otherwise directed.
Adverse Effects (≥1%)GI: Diarrhea
, abdominal cramps,
anorexia, hepatotoxicity. Skin:
Skin eruptions. Special Senses:
Ototoxicity. Body as a Whole:
Potential for superinfections.
levels and toxicities of alfentanil, bexarotene, carbamazepine, cevimeline, cilostazol, clozapine, cyclosporine, disopyramide, estazolam, fentanyl, midazolam, methadone, modafinil, quinidine, sirolimus, digoxin, theophylline, triazolam, warfarin
are increased. Ergotamine
may increase peripheral vasospasm. May increase risk of arrhythmias.
Readily absorbed from GI tract. Peak:
2 h. Distribution:
Concentrates in liver; crosses placenta; distributed into breast milk. Metabolism:
In liver. Elimination:
Primarily in bile and feces. Half-Life:
Assessment & Drug Effects
- Lab tests: Determine C&S prior to treatment. Periodic liver function tests and blood cell counts if therapy is prolonged 10
- Cholestatic hepatitis syndrome is most likely to occur in adults who have received erythromycin estolate for >10 d or who
have had repeated courses of therapy. The condition generally clears within 35 d after cessation of therapy.
Patient & Family Education
- Advise patient to report immediately the onset of adverse reactions and to be on the alert for signs and symptoms associated
with jaundice (see Appendix F).
- Ototoxicity is most likely to occur in patients receiving high dosage or who have impaired kidney function. Report immediately
the onset of tinnitus, vertigo, or hearing impairment.